-
公开(公告)号:US20160368884A1
公开(公告)日:2016-12-22
申请号:US15152902
申请日:2016-05-12
Applicant: H. Lundbeck A/S
Inventor: Heidi Lopez de Diego , Kim Lasse Christensen , Rene Holm , Jens Kateb
IPC: C07D295/096 , C07D207/28
CPC classification number: C07D295/096 , C07D207/28
Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
Abstract translation: 本发明提供了含有所述盐的伏妥妥汀焦谷氨酸盐和药物组合物。
-
22.1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment 有权
Title translation: 1- [2-(2,4-二甲基苯基硫基) - 苯基]哌嗪作为联合5-羟色胺再摄取的化合物,5-HT3和5-HT1a用于治疗认知功能障碍的活性公开(公告)号:US20140315921A1
公开(公告)日:2014-10-23
申请号:US14326725
申请日:2014-07-09
Applicant: H. Lundbeck A/S
Inventor: Benny Bang-Andersen , Andre Faldt , Arne Mork , Heidi Lopez de Diego , Rene Holm , Tine Bryan Stensbol , Nicholas Moore
IPC: C07D295/096
CPC classification number: A61K31/495 , A61K9/14 , C07D295/096 , Y10T428/2982
Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
Abstract translation: 本公开涉及结晶形式的1- [2-(2,4-二甲基苯基硫烷基) - 苯基]哌嗪或其药学上可接受的盐。
-
公开(公告)号:US08754217B2
公开(公告)日:2014-06-17
申请号:US13926427
申请日:2013-06-25
Applicant: H. Lundbeck A/S , Biotie Therapies Corp.
Inventor: Heidi Lopez de Diego , Carla De Faveri , Florian Anton Martin Huber
IPC: C07D489/08
CPC classification number: C07D489/08
Abstract: The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.
Abstract translation: 本发明涉及盐酸纳美芬二氢盐,盐酸纳美芬酸二水合物的制备方法,包含盐酸纳美芬二水合物的药物组合物和包括给予盐酸纳美芬二水合物的方法。
-
-